Ignacio Monedero elected as Chair of the Core Group of Global Drug-resistant TB Initiative (GDI)
Ignacio Monedero Recuero (Nacho) is a physician from Spain with 18 years of experience in programmatic and clinical DR-TB and TB-HIV management for The Union, WHO and other agencies with field experience in more than 35 countries of Africa, Middle East, Latin America and South East Asia. He has delivered more than 90 international clinical/programmatic DR-TB trainings and more than 45 technical assistance missions mainly in DR-TB. He did a Master in Public Health in developing countries (LHSTM, London, 2006) and a PhD in DR-TB management in low- and middle-income countries (UAB, Barcelona, 2013) and is the author of more than 30 peer reviewed publications and collaborator/co-author of WHO, PAHO and Union guidelines. He is an international PMDT expert and clinical advisor for DR-TB outbreaks and difficult to manage cases jointly with member of Drug Safety and Monitoring Board of different clinical trials. Also involved in TB elimination, TPT and management of DR-TB in children and vulnerable populations projects.He is an active member of the EMRO rGLC core group since 2017 and GDI member since 2018, being the vicechair from 2021 to 2023; elected GDI chair in November 2023.
Dr Xiaolin Wei to serve as vice-chair of the Core Group of Global Drug-resistant TB Initiative (GDI)
Dr Wei is a medical doctor, public health specialists, tenured Full Professor and the inaugural Dalla Lana Chair of Global Health Policy in the University of Toronto. In 2022, he was elected as a Fellow of the Canadian Academy of Health Sciences, one of the highest honors for medical science academics in Canada. His research programs have combined rigorous implementation science methods in evaluating health interventions. His scholarship has transformed research evidence into highly impactful programs informing management of diabetes, hypertension, tuberculosis, antibiotics and COVID-19.
Dr. Wei has over 20 years of experience of working with various national tuberculosis programs. He has served as a board member, and then the Secretary General and Vice President of the International Union Against Tuberculosis and Lung Disease for 12 years. Xiaolin has published over 150 papers in international peer-reviewed journals and obtained over US$10m of external funds. His work has directly influenced tuberculosis diagnosis, treatment, and management policies at national and global levels.